The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single cell analysis of urothelial carcinoma (UC) liver metastases identifies epithelial-mesenchymal transition (EMT) as a potential mechanism of resistance to immunotherapy.
 
Michael Lattanzi
No Relationships to Disclose
 
Lily M. Tredwin
No Relationships to Disclose
 
Fang-Ming Deng
No Relationships to Disclose
 
Luis Chiriboga
No Relationships to Disclose
 
Briana Zeck
No Relationships to Disclose
 
Claudio Forcato
Employment - Menarini Silicon Biosystems
 
Jonathan Serrano
No Relationships to Disclose
 
Hussein Mohamed
No Relationships to Disclose
 
Matija Snuderl
Stock and Other Ownership Interests - Acceleron Pharma; Arca Biopharma; Bluebird Bio; Catalyst Pharmaceuticals; Cellceutix Corporation; Epizyme; Geron; Isis Pharmaceuticals; SEVA Therapeutics
Travel, Accommodations, Expenses - Silicon Biosytems
 
Arjun Vasant Balar
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Genentech/Roche; Incyte; Merck; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen